Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. - Wikidata - awgldk - TriplyDB

Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.

Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.

http://www.wikidata.org/entity/Q34658876

about

Immunosuppressive agents for treating IgA nephropathy Non-immunosuppressive treatment for IgA nephropathy New developments in the genetics, pathogenesis, and therapy of IgA nephropathy Microbiota and metabolome associated with immunoglobulin A nephropathy (IgAN).Steroids in the treatment of IgA nephropathy to the improvement of renal survival: a systematic review and meta-analysis.Efficacy and safety of mycophenolate mofetil in patients with IgA nephropathy: an update meta-analysis Tubulointerstitial nephritis and uveitis syndrome complicated by IgA nephropathy and Graves' disease: a case report Corticosteroid therapy in IgA nephropathy.Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy.Aberrantly glycosylated IgA1 as a factor in the pathogenesis of IgA nephropathy Long-term results of a randomized controlled trial in childhood IgA nephropathy.The need for improved uptake of the KDIGO glomerulonephritis guidelines into clinical practice in Canada: a survey of nephrologists.Genome-wide scan identifies a copy number variable region at 3p21.1 that influences the TLR9 expression levels in IgA nephropathy patients Long-term kidney survival analyses in IgA nephropathy patients under steroids therapy: a case control study.Tacrolimus restores podocyte injury and stabilizes the expression of Cabin1 in 5/6 nephrectomized rats.Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series.Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study.Corticosteroid Treatment Influences TA-Proteinuria and Renal Survival in IgA Nephropathy.The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression Use of low-dose sulodexide in IgA nephropathy patients on renin-angiotensin system blockades Recurrent glomerulonephritis under rapid discontinuation of steroids.Tacrolimus combined with low-dose corticosteroids is an effective and safe therapeutic option for refractory IgA nephropathy.Glomerular diseases: emerging tests and therapies for IgA nephropathy Multiple rare genetic variants co-segregating with familial IgA nephropathy all act within a single immune-related network.Treatment of IgA nephropathy: an update.Treatment of IgA nephropathy and Henoch-Schönlein nephritis.Pathology of IgA nephropathy.Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.Emerging therapies in immunoglobulin A nephropathy.Identification of novel molecular signatures of IgA nephropathy through an integrative -omics analysis.Treatment of IgA nephropathy with renal insufficiency.Highlights of the 2015 ERA-EDTA Congress--glomerular diseases.Corticosteroids in IgA Nephropathy: Lessons from Recent Studies.Why, when and how should immunosuppressive therapy considered in patients with immunoglobulin A nephropathy?Inflammation in IgA nephropathy.The risk of recurrent IgA nephropathy in a steroid-free protocol and other modifying immunosuppression.Is there a role for immunosuppression in immunoglobulin A nephropathy?Pro: STOP immunosuppression in IgA nephropathy?Therapeutic variability in adult minimal change disease and focal segmental glomerulosclerosis.

P2860

Q24188035-E9D658BA-3679-4CC1-9F70-04958A5D8C62 Q24235956-6465852F-6D7E-4DE3-A581-EC316709D6E3 Q26786248-89BD37B2-AD1F-4360-8AB9-553C05854DA8 Q33748498-7773A756-5541-4947-9561-6688A1F981CA Q33886910-52EEF98D-691C-4465-8672-24FCF0C27FE5 Q33919210-DB781E63-B0B8-416C-A50D-577BFEC5811D Q34212509-5E85699D-07D2-4027-9D80-C442683E8CC0 Q34249313-D674BC03-D98C-4177-9DF1-4E116770A86E Q34284540-DDCE46F2-9A21-498B-A58E-1D8ECFE4CF4B Q34455482-25397FC5-3E8D-4076-B341-1A865F2FB7C2 Q34557198-2C4C56BE-8D15-429D-89F7-5C705FC457EE Q35030576-88ACB395-2163-4B1B-8EDC-E8638F0BF7F2 Q35310613-2B96A8A5-AFFC-4A28-8E68-A9A1A7C9F2DB Q35722106-3D4CE3BF-F012-4C0E-BFB6-17F6033FD866 Q35743170-3B7BF24F-1DC8-4FD8-AD45-74C4E8D377E0 Q35932322-6142AB2D-66DC-46F4-982F-ECC0C2660087 Q35976834-46588956-FE8A-4DA5-B79A-E7500A6A89CF Q36003136-062E598A-7D03-4B00-8CB5-FD61B53B1215 Q36077744-A88E5E51-293D-4943-9C96-33D18F3D1E2E Q36237466-50A22CEC-9126-4528-AC86-30D043A1BCFF Q36471767-FB127786-CE07-4FEE-B81D-236A583C0605 Q36790053-14AF557E-6DC5-4864-BB92-8F6962130F5D Q37205233-FE2F18E8-A2D5-43B9-9D5C-C6FE4492FD12 Q37621563-90C22790-D02F-423B-A1C8-1623900A9B27 Q37631861-DC35E3F3-58F2-455F-BF93-D66DB48B4E6C Q37939849-6454BA0C-857C-49A1-B3E8-1E970C6338A6 Q38094888-87CBB516-F763-4898-8C11-83C6A5682894 Q38214812-574CD293-C80B-4C79-BC33-050B455AC538 Q38372995-2578FC9D-2614-4571-8293-493AB93ECF91 Q38511505-5423E2F9-0CC3-4876-9971-1DD20A6F0309 Q38613296-9D3310B2-302C-4DD5-8B2F-AB9E3722557D Q38689787-A153BB59-D9B6-4283-8866-F3D1A8D13C0D Q38695675-8040208B-998E-455F-88FE-4C4F1E821BCE Q38817381-03353EC4-5075-4204-85EA-D9703903D99F Q38860793-AB9367F9-F269-4DB4-B6F0-612DB3160166 Q39178756-B6D94CE8-270C-4465-AE39-587366A582FE Q39185490-20F6C6FA-ECA6-48F4-ADD6-B84B1BBE1D8A Q39229309-E8339B4B-A21A-480C-94F8-0E295413FA09 Q39497940-4A3E6201-F638-4F42-99F5-389FC6C91BE8 Q39701489-0BD500B9-CF4D-4015-B0EA-C582F57CD479

P2860

Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.

http://www.wikidata.org/entity/Q34658876

description

2009 nî lūn-bûn

@nan

2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Randomized controlled clinical ...... n proteinuric IgA nephropathy.

@ast

Randomized controlled clinical ...... n proteinuric IgA nephropathy.

@en

Randomized controlled clinical ...... n proteinuric IgA nephropathy.

@nl

type

label

Randomized controlled clinical ...... n proteinuric IgA nephropathy.

@ast

Randomized controlled clinical ...... n proteinuric IgA nephropathy.

@en

Randomized controlled clinical ...... n proteinuric IgA nephropathy.

@nl

prefLabel

Randomized controlled clinical ...... n proteinuric IgA nephropathy.

@ast

Randomized controlled clinical ...... n proteinuric IgA nephropathy.

@en

Randomized controlled clinical ...... n proteinuric IgA nephropathy.

@nl

P1433

Q34658876-EC9568F8-A780-45EA-8BFE-49810DAAD91E

P1476

Q34658876-25EE0323-2A6A-418C-AB75-0C543667F8F3

P2093

Q34658876-2CFA6087-1B87-4A82-BA56-79E2A23392CA

Q34658876-3B073DD9-2953-4102-8B6B-5E641B8C1DA0

Q34658876-D2BA3DDB-23F5-4407-8CB4-D91FEEA6D756

P2860

Q34658876-1A933092-50D1-4D86-9D5F-18B01A892321

Q34658876-3647B4FD-341D-46A1-8473-3614AEF9DAD1

Q34658876-382446AD-30EF-4CAF-A950-20D5A9E99AE0

Q34658876-3BE027FB-7895-41F6-A7ED-575121640E2B

Q34658876-431A44FD-B3EF-4DC5-A8B7-24A2EFA84CE7

Q34658876-56E448AA-D464-4CF6-8EA1-CED0AA692668

Q34658876-69A9839C-3042-46FC-9B6E-2657688AEB60

Q34658876-8A9CC1BF-3C1E-4695-A7A6-089F34CF419E

Q34658876-AA1FAA78-E1E4-42CD-B3C1-7F6F217A61C4

Q34658876-AD0678FA-5736-4B51-AA31-F8A593C25EED

P304

Q34658876-074CF71F-3E67-45DB-903E-23EE4716CED6

P31

Q34658876-D4E5140D-8E87-40B5-BAD5-290245FB2583

P356

Q34658876-DF09E58D-B7E8-44BB-AC45-948E99688DCC

P407

Q34658876-26BED239-EDD5-4CE0-BE35-F7B50461C174

P433

Q34658876-08174B80-B905-4C9E-9BFF-626CCF0C54AA

P478

Q34658876-7158B546-A7C4-488D-A7C3-2BF5CCA5BB59

P50

Q34658876-170B4241-966A-4CF8-8FEE-2159EAF8A541

Q34658876-EB3481DB-3BF7-449A-AD33-E544DA851DC2

P577

Q34658876-2EFDE5A2-E52E-47D6-A378-300334D6E383

P698

Q34658876-4EBE955D-1C34-4220-993D-12E3F2AC417A

P356

P1433

Nephrology Dialysis Transplantation

P1476

Randomized controlled clinical ...... in proteinuric IgA nephropathy

@en

P2093

Diletta Domenica Torres

http://www.w3.org/2001/XMLSchema#string

Francesco Paolo Schena

http://www.w3.org/2001/XMLSchema#string

Michele Rossini

http://www.w3.org/2001/XMLSchema#string

P2860

An "evidence-based" survey of therapeutic options for IgA nephropathy: assessment and criticism.

Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy.

Potential for extending survival of peripheral intravenous infusions.

A retrospective analysis of the natural history of primary IgA nephropathy worldwide.

Survey of the Italian Registry of Renal Biopsies. Frequency of the renal diseases for 7 consecutive years. The Italian Group of Renal Immunopathology.

Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial.

Corticosteroids in IgA nephropathy: a randomised controlled trial.

Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy.

Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial.

Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial.

P304

3694-3701

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NDT/GFP356

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Francesco Pesce

P577

2009-07-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19628647

http://www.w3.org/2001/XMLSchema#string